Investigation Report on China’s Montelukast Market, 2018-2022

$2,200$3,300

Clear
SKU: 1811351 Categories: , Tag:

Description

Description
More than 300 million people in the world are suffering from seasonal asthma of varying degrees. The number is higher in countries with severe environmental pollution and high tobacco consumption. Asthma and allergic rhinitis are common nowadays. Owing to heavy air pollution, the incidences of these diseases are increasing year by year.
Montelukast, developed by MSD, is widely used in the treatment of allergic rhinitis and asthma. As a selective leukotriene D4 receptor antagonist, it selectively binds to the leukotrienes in the airway, blocks the action of allergic mediators, reduces airway inflammation, and makes the airway unobstructed. In 1998, Montelukast sodium tablets (10 mg) and chewable tablets (5 mg) were approved by the FDA and first marketed in the U.S. in the trade name of “Singulair”. In 2000 and 2002, Montelukast chewable tablets (4 mg) and granules (4 mg) were approved for sale, mainly for the prevention and long-term treatment of asthma in adults and children aged above 2.
In 1999, MSD’s Montelukast chewable tablets (5mg) and tablets (10mg) were approved to enter China in the trade name of “Singulair”, followed by Montelukast chewable tablets (4mg) and granules (4mg). In 2006, the generic Montelukast tablets (10mg) and chewable tablets (5mg) by Sichuan Otsuka Pharmaceutical Co., Ltd. were approved to be sold in the trade name of “Bystine”. Many other companies in China have also filed applications for generic Montelukast.
According to CRI’s market research, from 2005 to 2010, the annual sales value of Montelukast in China grew at a CAGR of more than 40%. As competing products emerged, the growth rate slowed down from 2011 but stays above 10%. In 2017, the market size of Montelukast was about CNY 552 million. The market was dominated by MSD, Lunan Better Pharmaceutical Co., Ltd., and Sichuan Otsuka Pharmaceutical Co., Ltd. Declining in recent years, the market share by sales value of MSD was close to 73%.
According to statistics, there are more than 30 million asthma patients and 300 million to 400 million patients with allergic rhinitis in China. And the numbers will continue to rise with increasingly serious environmental pollution. In China, Montelukast is considered as one of the best anti-asthmatic drugs, which promises huge market potential.

Topics Covered:
– Situation of respiratory diseases in China
– Supply and sales of Montelukast in China
– Prices of Montelukast in China
– Competition on China’s Montelukast market
– Market share of Montelukast manufacturers in China
– Prospect of China’s Montelukast Market, 2018-2022

Table of Contents

Table of Contents
1 Basic Concept of Montelukast
1.1 Indications for Montelukast
1.2 Development of Montelukast in China
1.3 Government Approval of Montelukast in China

2 Sales of Montelukast in China, 2013-2017
2.1 Sales Value of Montelukast
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Montelukast
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Montelukast by Dosage Form in China, 2013-2017
2.3.1 Tablets
2.3.2 Granules

3 Analysis on Major Montelukast Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Montelukast Manufacturers 3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 MSD
3.2.1 Enterprise Profile
3.2.2 Sales of MSD’s Montelukast in China
3.3 Lunan Better Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Lunan Better Pharmaceutical Co., Ltd.’s Montelukast in China
3.4 Sichuan Otsuka Pharmaceutical Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Sichuan Otsuka Pharmaceutical Co., Ltd.’s Montelukast in China
4 Prices of Montelukast in China, 2017-2018
4.1 MSD (Singulair)
4.2 Lunan Better Pharmaceutical Co., Ltd. (Pingqi)
4.3 Sichuan Otsuka Pharmaceutical Co., Ltd. (Bystine)

5 Prospect of China’s Montelukast Market, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend
Selected Charts
Chart Governmental Approval of Montelukast in China
Chart Sales Value of Montelukast in China, 2013-2017
Chart Sales Value of Montelukast in Parts of China, 2013-2017
Chart Sales Volume of Montelukast in China, 2013-2017
Chart Sales Volume of Montelukast in Parts of China, 2013-2017
Chart Sales Value of Montelukast Tablets in China, 2013-2017
Chart Sales Value of Montelukast Granules in China, 2013-2017
Chart Market Share by Sales Value of Top 3 Montelukast Manufacturers, 2013-2017
Chart Market Share by Sales Volume of Top 3 Montelukast Manufacturers, 2013-2017
Chart Sales Value of MSD’s Montelukast, 2013-2017
Chart Sales Volume of MSD’s Montelukast, 2013-2017
Chart Sales Value of Lunan Better Pharmaceutical Co., Ltd.’s Montelukast, 2013-2017
Chart Sales Volume of Lunan Better Pharmaceutical Co., Ltd.’s Montelukast, 2013-2017
Chart Sales Value of Sichuan Otsuka Pharmaceutical Co., Ltd.’s Montelukast, 2013-2017
Chart Sales Volume of Sichuan Otsuka Pharmaceutical Co., Ltd.’s Montelukast, 2013-2017
Chart Prices of MSD’s Montelukast in Parts of China, 2017-2018
Chart Prices of Lunan Better Pharmaceutical Co., Ltd.’s Montelukast in Parts of China, 2017-2018
Chart Prices of Sichuan Otsuka Pharmaceutical Co., Ltd.’s Montelukast in Parts of China, 2017-2018
Chart Forecast on Sales Volume of Montelukast in China, 2018-2022

Additional information

Publisher

Geography Covered

Date Published

Pages

Charts

Format